

=> d his

(FILE 'HOME' ENTERED AT 07:18:32 ON 13 NOV 2002)

FILE 'REGISTRY' ENTERED AT 07:18:36 ON 13 NOV 2002

L1 STRUCTURE UPLOADED

L2 25 S L1 FULL

L3 18 S L2 AND 1/P

FILE 'USPATFULL' ENTERED AT 07:19:49 ON 13 NOV 2002

L4 2 S L3

FILE 'CAPLUS' ENTERED AT 07:20:53 ON 13 NOV 2002

L5 8 S L3

FILE 'BEILSTEIN' ENTERED AT 07:26:47 ON 13 NOV 2002

L6 3 S L3 FULL

FILE 'CAOLD' ENTERED AT 07:29:26 ON 13 NOV 2002

L7 1 S L3

SEL AN 1-

FILE 'CAPLUS' ENTERED AT 07:29:50 ON 13 NOV 2002

L8 2 S E1/OREF

09/857,078

Page 1

=> d ibib ab hitstr 1-2

=> d ibib ab hitstr

L4 ANSWER 1 OF 2 USPATFULL
 ACCESSION NUMBER: 96:19086 USPATFULL
 TITLE: Spontaneously dispersible concentrates and aqueous microemulsions with steryl retinates having anti-tumor activity
 INVENTOR(S): Eugster, Carl, Riehen, Switzerland
 Eugster, Conrad H., Wallisellen, Switzerland
 Haldemann, Walter, Binningen, Switzerland
 Rivara, Giorgio, Turin, Italy
 PATENT ASSIGNEE(S): Marigen S.A., Riehen, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5496813		19960305
APPLICATION INFO.:	US 1992-3997		19920813 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1991-6257	19910128
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kestler, Kimberly J.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	1050	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB There are described spontaneously dispersible agents containing sterolester and/or sterolphosphor compounds having a pronounced antitumour activity. Novel sterolesters and sterolphosphor compounds, their use for treating tumors, and processes for their preparation are disclosed.

IT 144338-33-0P 144338-34-1P 144338-35-2P
 144338-46-5P

(prepn. of, as neoplasm inhibitor)


RN 144338-33-0 USPATFULL
 CN Retinol, (3.beta.,22E)-ergosta-5,7,22-trien-3-yl hydrogen phosphate (9CI)
 (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 1 OF 2 USPATFULL (Continued)

PAGE 1-A



PAGE 1-B




RN 144338-46-5 USPATFULL
 CN Stigmasta-5,22-dien-3-ol, 2,3-bis[(1-oxohexadecyl)oxy]propyl hydrogen phosphate, (3.beta.,22E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L4 ANSWER 1 OF 2 USPATFULL (Continued)


PAGE 1-B



RN 144338-34-1 USPATFULL
 CN Ergosta-5,7,22-trien-3-ol, 3,7-dimethyl-2,6-octadienyl hydrogen phosphate, [3.beta.(E),22E]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


Pr-i

RN 144338-35-2 USPATFULL
 CN Ergosta-5,7,22-trien-3-ol, 3,7,11-trimethyl-2,6,10-dodecatrienyl hydrogen phosphate, (3.beta.,22E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.

L4 ANSWER 1 OF 2 USPATFULL (Continued)

PAGE 1-A



PAGE 1-B

Pr-i

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1996:631950 CAPLUS
 DOCUMENT NUMBER: 125:256745
 TITLE: Cosmetic composition based on lipid vesicles containing acids and its use in topical application
 INVENTOR(S): Terren, Nadia; Percin, Martine; Michelet, Jacques
 PATENT ASSIGNEE(S): Oreal S. A., Fr.
 SOURCE: Eur. Pat. Appl., 20 pp.
 CODEN: EPXKXW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 728459	A1	19960828	EP 1996-400163	19960123
EP 728459	B1	19970326		
R: DE, ES, FR, GB, IT				
FR 2730928	A1	19960830	FR 1995-2136	19950223
FR 2730928	B1	19970404		
ES 2102919	T3	19970801	ES 1996-400163	19960123
CN 1136430	A	19961127	CN 1996-106076	19960222
JP 08245338	A2	19960924	JP 1996-36860	19960223
BR 9600613	A	19971230	BR 1996-613	19960223
US 5804216	A	19980908	US 1996-605921	19960223

PRIORITY APPLN. INFO.: FR 1995-2136 A 19950223

OTHER SOURCE(S): MARPAT 125:256745

AB Cosmetic compns. based on lipid vesicles contg. acids, pH 4-6. Itoreq. 5, are disclosed. A cosmetic foundation contained General 122E5 1.6, hydrogenated lecithin 2.4, Me p-hydroxybenzoate 0.2, guanoxine 0.01, glycerin 3, propylene glycol 3, palm oil 6.5, apricot kernel oil 9.5, Bu p-hydroxybenzoate 0.09, Pr p-hydroxybenzoate 0.1, volatile silicone 7158, vitamin E acetate 0.5, Givaudan 1, yellow iron oxide 0.89, brown iron oxide 0.49, black iron oxide 0.11, titanium oxide 5.51, preservative 0.3, Sepigel 305 2, mixt. of .alpha.-hydroxyacids 1, crosslinked starch 3, and water q.s. 100 g.

IT 4358-16-1D, Cholesterol phosphate, alk. salts

RI: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)


(cosmetic compn. based on lipid vesicles contg. acids and its use in topical application)

RN 4358-16-1 CAPLUS

CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS (Continued)



=> d ibib ab hitstr 15 1-31

L5 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2003:117584 CAPLUS
 DOCUMENT NUMBER: 138:158560
 TITLE: Composition based on lipid lamellar vesicles incorporating at least a DHEA compound
 INVENTOR(S): Simonnet, Jean-Thierry
 PATENT ASSIGNEE(S): L'oreal, Fr.
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011245	A1	20030213	WO 2002-FR2571	20020718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

FR 2827765 A1 20030131 FR 2001-10109 20010727
 PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 138:158560

AB The invention concerns a compn. comprising: a dispersion, in an external aq. phase, of vesicles consisting of lipid lamellar phases sepd. from one another by hydrophilic layers and encapsulating a hydrophilic core, said lamellar phases comprising at least an amphiphilic lipid; and at least a DHEA compd. contained, in solubilized form in free mol. state, in particular non-complexed, in the hydrophilic layers and/or in the hydrophilic core; and at least a solubilizer of said DHEA compd. (preferably a glycol optionally combined with water and/or glycerin). The incorporation of the DHEA compd. in the hydrophilic core of the vesicles enable to prevent its recrystn. in the external aq. phase and to improve its bioavailability.

IT 4358-16-1, Cholesteryl phosphate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compn. based on lipid lamellar vesicles incorporating at least DHEA compd.)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:931764 CAPLUS
 DOCUMENT NUMBER: 137:389025
 TITLE: Foamy cosmetic cream containing fibers and surfactants
 INVENTOR(S): Guirmand, Carole; Hurel, Valerie
 PATENT ASSIGNEE(S): L'oreal, Fr.
 SOURCE: Fr. Demande, 24 pp.
 CODEN: FROXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2824265	A1	20021108	FR 2001-5927	20010503
JP 2003026564	A2	20030129	JP 2002-129209	20020430
US 2003024556	A1	20030206	US 2002-137353	20020503

PRIORITY APPLN. INFO.:
 AB Foamy cosmetic cream contg. fibers and surfactants with good phys. stability at 45.degree. are used for removing makeups and cleaning hair. Formulation of two cosmetic creams contg. 2% cocoacyl glucoside and 5% polyamide fibers are disclosed.
 IT 4358-16-1D, Cholesterol phosphate, alkali salts
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (foamy cosmetic cream contg. fibers and surfactants)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:169063 CAPLUS
 DOCUMENT NUMBER: 136:221531
 TITLE: Foaming cosmetic cream for the treatment of fatty skins
 INVENTOR(S): Picard-Lesbouseyries, Elisabeth; Guillou, Veronique
 PATENT ASSIGNEE(S): L'oreal, Fr.
 SOURCE: Eur. Pat. Appl., 13 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1184031	A2	20020306	EP 2001-401904	20010716
EP 1184031	A3	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2813189	A1	20020301	FR 2000-11130	20000831
FR 2813189	B1	20030228		
JP 2002145736	A2	20020522	JP 2001-256752	20010827
CN 1342452	A	20020403	CN 2001-125899	20010830
US 2002058010	A1	20020516	US 2001-941589	20010830

PRIORITY APPLN. INFO.:
 AB A foaming cosmetic cream for treatment of fatty skins comprise a surfactant system and antilobolts or antiseborrhea agents. A foaming cosmetic cream contained preservatives 0.4, tetrasodium EDTA 0.2, potassium hydroxide 7, glycerin 7, PEG-8 7, lauric acid 3, myristic acid 20, palmitic acid 3, stearic acid 3, glyceryl stearate 5, cocoyl glucoside 2, azelaic acid 5, and water q.s. 100%.
 IT 4358-16-1D, Cholesteryl phosphate, alkali salts
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (foaming cosmetic cream for treatment of fatty skins)

RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



L5 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:873173 CAPLUS
 DOCUMENT NUMBER: 136:10921
 TITLE: Oil-in-water nanoemulsions containing anionic polymers for cosmetic, pharmaceutical skin and/or ophthalmic compositions
 INVENTOR(S): Sonnevile, Aubrun Odile; Simonnet, Jean Thierry
 PATENT ASSIGNEE(S): L'oreal S. A., Fr.
 SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
 CODEN: JKOXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001335424	A2	20011204	JP 2001-144925	20010515
FR 2809010	A1	20011123	FR 2000-6511	20000522
FR 2809010	B1	20020712		
EP 1160005	A1	20011205	EP 2001-401040	20010424
EP 1160005	B1	20020807		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
 AT 221800 E 20020815 AT 2001-1401040 20010424
 ES 2181662 T3 20030301 ES 2001-1401040 20010424
 PRIORITY APPL. INFO.: FR 2000-6511 A 20000522
 OTHER SOURCE(S): MARPAT 136:10921


AB The invention relates to a transparent oil-in-water nanoemulsion compn. having improved storage stability, wherein the nanoemulsion contains (1) nonionic and/or anionic amphipathic lipid, (2) anionic polymer having .gtoreq. 1 hydrophobic chain, e.g. a mixed ester from fatty acid; fatty alc., carboxylic acid, and glycerol, alkyl ether citrate, alkenyl succinate, and/or phosphate fatty ester, and wherein the ratio of the amphipathic lipid/the oily phase is 1.2-10. A cream contg. polyethylene glycol isostearate 4.5, disodium acyl glutamate 0.5, iso-Pr myristate 5, isocetyl stearate 10, dipropylene glycol 10, glycerol 5, polyoxyethylene C12-24 alc. copolymer-modified acrylate-acrylic acid copolymer (Synthalen V2000) 0.968, triethanolamine 0.194, and water q.s. to 100 % was formulated.

IT 4358-16-1D, Cholesterol phosphate, alkali salts
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oil-in-water nanoemulsions contg. anionic polymers and amphipathic lipids and other components for cosmetic, pharmaceutical skin and/or ophthalmic compns.)

RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



L5 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:850724 CAPLUS
 DOCUMENT NUMBER: 135:376535
 TITLE: Composition for make-up or skin-care in a powdery form containing a particular binder
 INVENTOR(S): Hadasch, Anke; Lemann, Patricia; Simonnet, Jean-thierry
 PATENT ASSIGNEE(S): L'oreal, Fr.
 SOURCE: Eur. Pat. Appl., 21 pp.
 CODEN: EPXDXW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1155676	A2	20011121	EP 2001-401249	20010515
EP 1155676	A3	20021218		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
 FR 2808999 A1 20011123 FR 2000-6448 20000519
 FR 2808999 B1 20021031
 JP 2002020236 A2 20020123 JP 2001-148415 20010517
 CN 1331967 A 20020123 CN 2001-122173 20010518
 US 2002041854 A1 20020411 US 2001-860567 20010521
 PRIORITY APPL. INFO.: FR 2000-6448 A 20000519
 OTHER SOURCE(S): MARPAT 135:376535

AB A make-up compn. contains a powdery phase and a binding phase which a continuous aq. phase. A binding phase contained iso-Pr myristate 1.64, castor oil 2.46, vaseline oil 12.36, liq. lanolin 1.26, water 70.95, imidazolinyl urea 0.3, glycerin 5, Acylglutamate HS-11 0.03, phytantriol 2.97, vaseline 2.28, chlorphenesine 0.25, and polyoxyethylene sorbitan monopalmitate 0.5%. A cosmetic make-up contained talc 77.06, iron oxide 2.74, Nylon powder 10, titanium oxide 1, preservative 0.2, and above binding phase 9%.

IT 4358-16-1, Cholesteryl phosphate
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (compn. for make-up or skin-care in powdery form contg. particular binder)

RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:568412 CAPLUS
 DOCUMENT NUMBER: 135:157367
 TITLE: Cationic polymer- and amphiphilic lipid-based oil-in-water nanoemulsions and their cosmetic applications
 INVENTOR(S): Douin, Veronique; Cazin, Benedicte; Decoster, Sandrine
 PATENT ASSIGNEE(S): L'oreal S. A., Fr.
 SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.
 CODEN: JKOXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001214081	A2	20010807	JP 2001-13866	20010122
FR 2804014	A1	20010727	FR 2000-792	20000121
FR 2804014	B1	20021018		
EP 1129684	A2	20010905	EP 2000-403527	20001214
EP 1129684	A3	20011114		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
 BR 2001000335 A 20011009 BR 2001-335 20010117
 US 2001028887 A1 20011011 US 2001-765675 20010122
 PRIORITY APPL. INFO.: FR 2000-792 A 20000121
 OTHER SOURCE(S): MARPAT 135:157367

AB The nanoemulsions (no.-av. diam. of oil drops <150 nm) contain oils, amphiphilic lipids (oil-to-amphiphilic lipid wt. ratio 1-10), and cationic polymers having .gtoreq.1 hydrophobic block and .gtoreq.1 hydrophilic block. A nanoemulsion (oil drop size .apprx.63 nm) contg. polyethylene glycol isostearate, behenyltrimethylammonium chloride (Genamin DDMP), avocado oil, jojoba oil, cyclopentadimethylsiloxane (DC 245), trimethylsilylamodimethicone microemulsion (SME 253), propylene glycol, ethoxylated sorbitan monolaurate (Tween 20), glycerol, quaternized alkyl hydroxyethyl cellulose (Quatrisoft LW 200), perfumes, and H2O showed good stability at 45.degree. for 2 mo, viscosity 650 mPa.s, and hair -conditioning effect.

IT 4358-16-1D, Cholesteryl phosphate, alkali metal salts
 RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
 (nanoemulsions contg. oils, amphiphilic lipids, and cationic polymers for cosmetics)

RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L5 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:49902 CAPLUS
 DOCUMENT NUMBER: 135:66070
 TITLE: Preparation and use of a composition based on lipid lamellar vesicles incorporating an aminophenol derivative
 INVENTOR(S): Chevalier, Veronique; Simonnet, Jean Thierry; Le Verge, Danielle
 PATENT ASSIGNEE(S): L'oreal, Fr.
 SOURCE: Fr. Demande, 27 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2796838	A1	20010202	FR 1999-9663	19990726
FR 2796838	A1	20010202	FR 1999-9663	19990726

PRIORITY APPLN. INFO.: MARPAT 135:66070
 OTHER SOURCE(S):
 AB The present invention concerns a compn. comprising vesicles formed from phases of lamellar lipids dispersed in an aq. phase, whereby the lamellar phases incorporate at least one aminophenol deriv. comprising a fatty acid chain with a polar head bound to a nitrogen atom of said aminophenol. The vesicles may have oily cores (oleosomes) or aq. cores (niosomes or liposomes). The aminophenol deriv. preferred is N-cholesteryl-4-aminophenol. The compn. is suitable for use in cosmetics
 IT 4358-16-1, Cholesterol phosphate
 RI: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (prepn. and use of a compn. based on lipid lamellar vesicles incorporating an aminophenol deriv.)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



L5 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:279407 CAPLUS
 DOCUMENT NUMBER: 134:300767
 TITLE: Use of ceramides for limiting the penetration in the skin or in keratin fibers of a cosmetic or pharmaceutical agent
 INVENTOR(S): Morancas, Jean-Luc; Philippe, Michel
 PATENT ASSIGNEE(S): L'oreal, Fr.
 SOURCE: Eur. Pat. Appl., 14 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1092428	A1	20010418	EP 2000-402569	20000918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2799650	A1	20010420	FR 1999-12832	19991014
FR 2799650	B1	20011207		
JP 2001114702	A2	20010424	JP 2000-314294	20001013
US 6497888	B1	20021224	US 2000-689636	20001013

PRIORITY APPLN. INFO.: FR 1999-12832 A 19991014
 OTHER SOURCE(S): MARPAT 134:300767
 AB Ceramides of the formula RICH(OH)CH(NHCO₂R')CH₂OH (R1 = satd. or unsatd. C1-32 alkyl groups substituted by hydroxyl groups and esterified by C1-35 acyl groups, R2 = satd. or unsatd. C1-50 substituted by hydroxyl groups and esterified by C1-30 acyl groups) are used for limiting the penetration of a cosmetic or pharmaceutical agent in the skin or in keratin fibers. A dispersion of vesicles was prepd. by dissolving 0.75 g of 2-(2'-hydroxyhexadecanoyl)amino octadecane-1,3-diol and 0.50 g of sodium cholesteryl sulfate in 40 ml of a mixt. of dichloromethane:methanol (50:50) and subjected to ultrasound at 40.degree.. The solvents were evapd. and Tris buffer pH = 6.75 was added sufficient enough to obtain a prepn. of 15 g of 54 lipids. The prepn. was subjected to ultrasound 6 times each time for 1 min to obtain vesicles having a diam of 152 nm. Formulation of a cosmetic comprising 33.3% of the above vesicles is disclosed.
 IT 4358-16-1, Cholesteryl phosphate
 RI: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of ceramides for limiting penetration in skin or in keratin fibers of cosmetic or pharmaceutical agent)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L5 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:891464 CAPLUS
 DOCUMENT NUMBER: 134:46650
 TITLE: Uses of ascorbyl-phosphoryl-cholesterol for topical compositions
 INVENTOR(S): Pchelintsev, Dmitri; Duffy, John A.; Kalafsky, Robert; Fahlek, Harold E.
 PATENT ASSIGNEE(S): Avon Products, Inc., USA
 SOURCE: U.S., 6 pp., Cont.-in-part of U.S. 5,922,335.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6362450	A	20001219	US 1998-189368	19981109
AT 187333	E	19991215	AT 1996-923191	19960514
ES 2142073	T3	20000401	ES 1996-923191	19960514
US 5866147	A	19990202	US 1997-837282	19970411
US 5951990	A	19990914	US 1997-853271	19970509
US 5922335	A	19990713	US 1998-126191	19980730
CA 2338325	AA	20000210	CA 1999-2338325	19990730
WO 200006091	A1	20000210	WO 1999-US17420	19990730

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 9952494 A1 20000221 AU 1999-52494 19990730
 EP 1100432 A1 20010523 EP 1999-937718 19990730
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
 JP 2002521411 T2 20020716 JP 2000-561948 19990730
 AU 9963071 A1 20000224 AU 1999-63071 19991203
 AU 740577 B2 20011108
 PRIORITY APPLN. INFO.: US 1995-440765 B1 19950515
 US 1997-837282 A2 19970411
 US 1997-853271 A2 19970509
 US 1998-126191 A2 19980730
 AU 1996-63770 A 19960514
 EP 1996-923191 A 19960514
 US 1998-189368 A 19981109
 WO 1999-US17420 W 19990730

AB The present invention relates to the use of 3'-(L-ascorbyl-2-o-phosphoryl)-cholesterol, 3'-(L-ascorbyl-3-o-phosphoryl)-cholesterol, and their deriva. (APC compds.). More specifically, the present invention relates to use of APC compds. to improve the appearance and health of skin, hair, lips and nails. The present invention also relates to methods of topically administering APC compds. to cleanse skin and remove make-up, moisturize skin, enhance the shine and wear of nail coating compns., and to improve compns. having pigments and/or iron oxides.
 IT 313055-94-6
 RI: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

L4 ANSWER 2 OF 2 USPATFULL
 ACCESSION NUMBER: 87:50484 USPATFULL
 TITLE: Steroids for the treatment of hypercholesterolemia
 INVENTOR(S): Cassal, Jean-Marie, Mulhouse, France
 PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4680290		19870714
APPLICATION INFO.:	US 1984-639543		19840810 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1983-4644	19830825
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Schenkman, Leonard	
LEGAL REPRESENTATIVE:	Saxe, Jon S., Leon, Bernard S., Boxer, Matthew	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1,17	
LINE COUNT:	476	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Steroids of the formula ##STR1## wherein n represents the number 2, 3 or 4; R.sup.1 represents hydrogen, lower-alkyl or lower-alkylidene; R.sup.2, R.sup.3 and R.sup.4 represent hydrogen or lower-alkyl and the dotted C-C bonds in the 5(6)-, 7(8)-, 22(23)-, 24(28)- and 25(26)-position are optional, whereby the B-ring can contain only one double bond and the side-chain is either saturated or is mono-unsaturated or is di-unsaturated in the 22(23), 25(26)-position; and whereby R.sup.1 is lower-alkyl or lower-alkylidene when a 5(6)-double bond is present, n is 2 and R.sup.2, R.sup.3 and R.sup.4 are methyl,

and pharmaceutically acceptable salts of these steroids have activity inhibiting the intestinal resorption of cholesterol. They can be manufactured from steroids which are otherwise substituted in the 3.beta.-position.

IT 98033-06-8P (prepn. and intestinal cholesterol absorption inhibiting activity of)
 RN 98033-06-8 USPATFULL
 CN Stigmasta-5,22-dien-3-ol, 2-(trimethylammonio)ethyl hydrogen phosphate, inner salt, (3.beta.,22E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L4 ANSWER 2 OF 2 USPATFULL (Continued)



09/857,078

Page 4

=> d ibib ab hitstr 1-8

L5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:381819 CAPLUS
 DOCUMENT NUMBER: 131:17689
 TITLE: Sterol phosphates
 INVENTOR(S): Subirana, Rafael Pi; Bigorra, Joaquin
 PATENT ASSIGNEE(S): Cognis Deutschland G.m.b.H., Germany
 SOURCE: Ger. Offen., 8 pp.
 CODEN: GWXXBX

DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19855956	A1	20000608	DE 1998-19855956	19981204
DE 19855956	C2	20001102		
WO 2000034307	A1	20000615	WO 1999-EP9114	19991125
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1135404	A1	20010926	EP 1999-965407	19991125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002531575	T2	20020924	JP 2000-586750	19991125
PRIORITY APPLN. INFO.: DE 1998-19855956 A 19981204				
WO 1999-EP9114 W 19991125				

OTHER SOURCE(S): MARPAT 133:17689

AB Sterol phosphates (1, R1, R2, R4 = H, Me; R3 = C1-15 alkyl or alkenyl) and their hardening products with polyphosphoric acid are prep. for use as serine esterase and serine proteinase inhibitors in personal deodorants. I do not irritate the skin or alter the normal skin microflora. Thus, 200 g lanosterol was dissolved in 400 mL n-pentane and heated with 58 g polyphosphoric acid at 70-75.degree. for 15 min, followed by refluxing at 80.degree. for 3.5 h, cooling, filtering, and washing with 200 mL 190-PrOH. The product was dissolved in H2O at 80.degree., filtered, and dried under vacuum.

IT 24352-61-2P 85135-03-1P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (sterol phosphates for deodorants)

RN 24352-61-2 CAPLUS

CN Lanosta-8,24-dien-3-ol, dihydrogen phosphate, (3.beta.,22E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 85135-03-1 CAPLUS
 CN Stigmasta-5,22-dien-3-ol, dihydrogen phosphate, (3.beta.,22E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:572523 CAPLUS
 DOCUMENT NUMBER: 123:228757
 TITLE: Synthesis and anti-HIV activity of steroidal prodrugs of 3'-azido-3'-deoxythymidine (AZT)
 AUTHOR(S): Balagopal, Meher I.; Ollapally, Abraham P.; Lee, Henry J.
 CORPORATE SOURCE: Dep. Chem., Florida A and M Univ., Tallahassee, FL, 32307, USA
 SOURCE: Cellular and Molecular Biology (Paris) (1995), 41(Suppl. 1), S1-S7
 CODEN: CMOBEP; ISSN: 0145-5680
 PUBLISHER: C.M.B. Association
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A total of seven steroidal prodrugs of AZT, e.g. I (R1 = R2 = H; R1 = H, R2 = CN; R1 = OH, R2 = H), were synthesized and tested in vitro for their anti-HIV activity. Three of them were steroidal carboxylic esters prep. from steroidal 17.beta.-carboxylic acids and AZT. The remaining four were alkyl steroidal phospho-triesters of AZT. These prodrugs were synthesized using known procedures. Preliminary results of in vitro anti-HIV activity screening showed that all of these prodrugs were active against HIV. While carboxylic esters showed comparable anti-HIV activity to that of AZT, phosphotriesters were less active than AZT. The therapeutic indexes of all these prodrugs are comparable to that of AZT.


IT 161084-72-6P 161168-70-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and anti-HIV activity of steroidal prodrugs of azidodeoxythymidine)

RN 161084-72-6 CAPLUS

CN 5'-Thymidylic acid, 3'-azido-3'-deoxy-, 2-cyanoethyl (3.beta.,22E,25R)-stigmasta-5,22-dien-3-yl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B

Pr-i

RN 161168-70-3 CAPLUS
 CN 5'-Thymidylic acid, 3'-azido-3'-deoxy-, 2-cyanoethyl (3.beta.,22E,25R)-stigmasta-5,22-dien-3-yl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-A

Pr-i

PAGE 1-B

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:213448 CAPLUS

DOCUMENT NUMBER: 122:16167

TITLE:
Synthesis and anti-HIV activity of alkyl steroidal
3'-azido-3'-deoxythymidin-5'-yl phosphotriesters as
prodrugs of AZT

AUTHOR(S):
Balagopal, Meher I.; Ollapally, Abraham P.; Lee,
Henry J.

CORPORATE SOURCE:
College of Pharmacy and Pharmaceutical Sciences,
Florida A & M Univ., Tallahassee, FL, 32307, USA

SOURCE:
Nucleosides & Nucleotides (1994), 13(9), 1843-53
CODEN: NUNUD5; ISSN: 0732-8311

PUBLISHER:
Dekker

DOCUMENT TYPE:
Journal

LANGUAGE:
English


OTHER SOURCE(S):
CASREACT 122:161167

AB Alkyl steroidal AZT 5'-monophosphate triesters are designed as lipophilic
prodrugs of AZT to improve its therapeutic efficiency. We have
synthesized four phosphotriesters of AZT, e.g. 1, in one-pot, using
phosphoramidite-phosphate triester methodol. This method afforded the
desired prodrugs in high yields under mild conditions. The in vitro
evaluation of anti-HIV activity of these prodrugs is also reported.

IT 161084-72-6P 161168-70-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(synthesis and anti-HIV activity of alkyl steroidal
azidothymidinyl phosphotriesters as prodrugs of AZT)

RN 161084-72-6 CAPLUS
CN 5'-Thymidylic acid, 3'-azido-3'-deoxy-, 2-cyanoethyl (3.beta.,22E,25R)-
stigmasta-5,22-dien-3-yl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1993:102310 CAPLUS

DOCUMENT NUMBER: 118:102310

TITLE:
Preparation of sterol esters and sterol phosphorus
compounds as neoplasm inhibitors

INVENTOR(S):
Eugster, Carl; Eugster, Conrad Hans; Haldemann,
Walter; Rivara, Giorgio

PATENT ASSIGNEE(S):
Marigen S.A., Switz.

SOURCE:
PCT Int. Appl., 93 pp.

COVEN: PIXXD2

DOCUMENT TYPE:
Patent

LANGUAGE:
German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9212989	A1	19920806	WO 1991-CH221	19911025
W: JP, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CH 681153	A	19930129	CH 1991-257	19910128
EP 548261	A1	19930630	EP 1991-917941	19911025
EP 548261	B1	19950510		
R: DE, FR, GB, IT				
JP 05505401	T2	19930812	JP 1991-516345	19911025
JP 2955018	B2	19991004		
RU 2113219	C1	19980620	RU 1991-5053147	19911025
US 5496813	A	19960305	US 1992-3997	19920813
PRIORITY APPLN. INFO.:			CH 1991-257	19910128
			WO 1991-CH221	19911025

OTHER SOURCE(S):
MARPAT 118:102310

AB Title compds., e.g., [I, II, III; R1 = C1-10 alkyl, C2-10 alkenyl; R2 =
R5 (CH:CHCHMe:CH) nCO2, R5 (CH:CHCHMe:CH) n (CH:CHCH:Me) nCH:CHCO2,
R6O2CH2CH(CO2R6)CH2OP(O)(XNa)O-, OP(O)(XNa)OR6; n = 1-5; R5 = Q1-Q4,
etc., R6 = C1-32 alkyl, C2-32 alkenyl, etc.; X = O, S], were prepd. Thus,
all-trans-retinoic acid in PhMe contg. cat. DMF was stirred 4 h with
(COCl)2; stigmasterol and 4-(dimethylamino)pyridine in PhMe were added and
the mixt. was refluxed 2 h to give stigmasterol all-trans-retinoate.
Title compds. were active against murine adenocarcinoma at dilns. of
(1:400,000)-(1:40,000,000). Generic formulations contg. title compds.
were prepd.

IT 144338-33-0P 144338-34-1P 144338-35-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(prepn. of, as neoplasm inhibitor)

RN 144338-33-0 CAPLUS

CN Retinol, (3.beta.,22E)-ergosta-5,7,22-trien-3-yl hydrogen phosphate (9CI)
(CA INDEX NAME)

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-B

Pr-1

RN 161168-70-3 CAPLUS

CN 5'-Thymidylic acid, 3'-azido-3'-deoxy-, 2-cyanoethyl (3.beta.,22E,25R)-
stigmasta-5,22-dien-3-yl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




PAGE 1-B


Pr-1

L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B



RN 144338-34-1 CAPLUS

CN Ergosta-5,7,22-trien-3-ol, 3,7-dimethyl-2,6-octadienyl hydrogen phosphate,
[3.beta.(E),22E]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-B

Pr-i


RN 144338-35-2 CAPLUS
 CN Ergosta-5,7,22-trien-3-ol, 3,7,11-trimethyl-2,6,10-dodecatrienyl hydrogen phosphate, (3.beta.,22E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B




RN 144338-46-5 CAPLUS
 CN Stigmasta-5,22-dien-3-ol, 2,3-bis[(1-oxohexadecyl)oxy]propyl hydrogen phosphate, (3.beta.,22E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 1-B

Pr-i

L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1985:505226 CAPLUS
 DOCUMENT NUMBER: 103:105226
 TITLE: Steroids
 INVENTOR(S): Cassal, Jean Marie
 PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 24 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 135762	A2	19850403	EP 1984-109517	19840809
EP 135762	A3	19860122		
EP 135762	B1	19881012		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
CA 1252778	A1	19890418	CA 1984-458711	19840712
DK 8403475	A	19850226	DK 1984-3475	19840713
FI 8402830	A	19850226	FI 1984-2830	19840713
JP 60061595	A2	19850409	JP 1984-157785	19840730
AT 37883	E	19881015	AT 1984-109517	19840809
US 4680290	A	19870714	US 1984-639543	19840810
ZA 8406430	A	19850424	ZA 1984-6430	19840817
IL 72725	A1	19880731	IL 1984-72725	19840820
AU 8432225	A1	19850228	AU 1984-32225	19840821
AU 574706	B2	19880714		
HU 34997	A2	19850528	HU 1984-3153	19840822
HU 189929	B	19860828		
NO 8403406	A	19850226	NO 1984-3406	19840824
NO 161679	B	19890605		
NO 161679	C	19890913		
ES 535391	A1	19851201	ES 1984-535391	19840824
ES 543646	A1	19860501	ES 1985-543646	19850530
PRIORITY APPLN. INFO.:			CH 1983-4644	19830825
			EP 1984-109517	19840809

AB Sterol phosphates I [R,R1,R2 = H, alkyl; Z = H2; H, alkyl; alkylidene; n = 2-4; optional 5-, 7-, 22-, 24(28)-, 25-unsatd.] were prepd. by phosphorylation of sterols and inhibited intestinal absorption of cholesterol. Thus, .beta.-sitosterol was treated with POCl3 in CHCl3 contg. quinine and then with choline tosylate to give stigmast-5-en-3.beta.-yloxyphosphorylcholine (II). At 100 .mu.mol/kg in animal tests II reduced intestinal cholesterol absorption 33% compared to controls.

IT 98033-06-8P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and intestinal cholesterol absorption inhibiting activity of)

RN 98033-06-8 CAPLUS

CN Stigmasta-5,22-dien-3-ol, 2-(trimethylammonio)ethyl hydrogen phosphate, inner salt, (3.beta.,22E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2002 ACS (Continued)



L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1983:198582 CAPLUS
 DOCUMENT NUMBER: 99:198582
 TITLE: Synthesis of steroid phosphates via monomeric metaphosphate
 AUTHOR(S): Ramirez, Fausto; Marecek, James F.; Yemul, Shrishailam S.
 CORPORATE SOURCE: Dep. Chem., State Univ. New York, Stony Brook, NY, 11794, USA
 SOURCE: J. Org. Chem. (1983), 48(9), 1417-20
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Steroid dihydrogen phosphate esters I, II, III, IV (R = Et), V (R = Me), and VI were prep'd. by a procedure that involves the monomeric metaphosphate anion as an intermediate. The source of metaphosphate is a 1:2 M mixt. of $\text{PhCBr}[\text{P}(\text{O})(\text{OH})_2]\text{CH}_2\text{Br}$ and $(\text{Me}_2\text{CH})_2\text{N}^+\text{Et}$ in 0.05 M CH_2Cl_2 at 20.degree.. Yields of steroid hydrogen phosphates with one or two double bonds range from 65 to 75%. III can be isolated in pure state, although in lower yield (46%) by this procedure.
 IT 24352-60-1P 85135-03-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, by phosphorylation with (phenyldibromoethyl)phosphonic acid)
 RN 24352-60-1 CAPLUS
 CN Ergosta-5,7,22-trien-3-ol, dihydrogen phosphate, (3.beta.,22E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 85135-03-1 CAPLUS
 CN Stigmasta-5,22-dien-3-ol, dihydrogen phosphate, (3.beta.,22E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2002 ACS (Continued)



L5 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1972:154006 CAPLUS
 DOCUMENT NUMBER: 76:154006
 TITLE: Organophosphorochloridates. VI. Reactions of steroid phosphorochloridates with amines and alcohols
 AUTHOR(S): Cremllyn, R. J. W.; Dewhurst, B. B.; Wakeford, D. H.; Raja, R. A.
 CORPORATE SOURCE: Dep. Chem. Sci., Hatfield Polytech., Hatfield, Engl.
 SOURCE: J. Chem. Soc., Perkin Trans. 1 (1972), (9-10), 1171-5
 CODEN: JCPAB4
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Cho-lesteryl phosphorodichloridate (I) was prep'd. (87%) by the action of $\text{NET}_3\text{-POCl}_3$ on cholesterol (II); I in CHCl_3 decompd. to II on a silica column; at 130.degree. I decompd. When I or its lanosteryl and ergosteryl analogs were treated with primary or secondary amines, nucleophilic substitution at P occurred; e.g., I with PhNH_2 gave cholesteryl N-phenylphosphoramidic chloride. Ergosteryl phos-phorodichloridate also underwent elimination at C-3 in amine reactions. trans-4-tert-Butylcyclohexanol with $\text{NET}_3\text{-POCl}_3$ or pyrophosphoryl chloride gave the phosphorodichloridate; with POCl_3 and a larger amt. of alc. bis(4-tert-butylcyclohexyl) phos-phorochloridate was obtained. The steroid phosphorodichlo-ridates reacted with alcs. to give phosphate esters.
 IT 36218-15-2P 36305-91-6P 36467-59-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 36218-15-2 CAPLUS
 CN Lanosta-8,24-dien-3-ol, dipropyl phosphate, (3.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 36305-91-6 CAPLUS
 CN Ergosta-5,7,22-trien-3-ol, diethyl phosphate, (3.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L5 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 36467-59-1 CAPLUS
 CN Lanosta-8,24-dien-3-ol, bis(1,1-dimethylethyl) phosphate, (3.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1970:3631 CAPLUS
 DOCUMENT NUMBER: 72:3631
 TITLE: Steroid phosphates and related compounds
 AUTHOR(S): Cremlyn, Richard J. W. C.; Olsson, N. A.
 CORPORATE SOURCE: Dep. Chem. Sci., Hatfield Polytech., Hatfield, Engl.
 SOURCE: J. Chem. Soc. C (1969), (17), 2305-10
 CODEN: J500AX
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The prepn. of cholesteryl dihydrogen phosphate via cholesteryl phosphorodichloride is described; although the reaction was successful for the prepn. of ergosteryl and lanosteryl phosphorodichlorides, it failed with cholestanol and thiocholesterol. Dicholesteryl phosphorochloride was prepd. but not diergosteryl or dilanosteryl phosphorochlorides. The hydrolysis of cholesteryl phosphorodichloride was examd. Reaction of thiophosphoryl chloride and cholesterol gave cholesteryl thionophosphorodichloride but this could not be hydrolyzed to the phosphate. Treatment of cholesterol with P2S5 gave O,O-dicholesteryl hydrogen phosphorodithioate contrary to previous reports. A study was made of the decompn. of cholesteryl phosphorodichloride in inert org. solvents.

IT 24352-60-1P 24352-61-2P 24352-62-3P
 24352-65-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 24352-60-1 CAPLUS
 CN Ergosta-5,7,22-trien-3-ol, dihydrogen phosphate, (3.beta.,22E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 24352-61-2 CAPLUS
 CN Lanosta-8,24-dien-3-ol, dihydrogen phosphate, (3.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 24352-62-3 CAPLUS
 CN Lanosta-8,24-dien-3.beta.-ol, dimethyl phosphate (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 24352-65-6 CAPLUS
 CN Ergosterol, dimethyl phosphate (8CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2002 ACS (Continued)


09/857,078

Page 10

=> d all 1-3

L6 ANSWER 1 OF 3 BEILSTEIN COPYRIGHT 2002 BEILSTEIN CDS MDL

Beilstein Records (BRN): 4587778
Beilstein Pref. RN (BPR): 24352-60-1
CAS Reg. No. (RN): 24352-60-1
Chemical Name (CN): phosphoric acid mono-(10,13-dimethyl-17-(1,4,5-trimethyl-hex-2-enyl)-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[*a*]phenanthren-3-yl) ester
Autonom Name (AUN): phosphoric acid mono-(10,13-dimethyl-17-(1,4,5-trimethyl-hex-2-enyl)-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[*a*]phenanthren-3-yl) ester
Molec. Formula (MF): C28 H45 O4 P
Molecular Weight (MW): 476.63
Lawson Number (LN): 5505
File Segment (FS): Stereo compound
Compound Type (CTYPE): isocyclic
Constitution ID (CONSID): 2269835
Tautomer ID (TAUTID): 4395299
Beilstein Citation (BSO): 5-06, 6-06
Entry Date (DED): 1991/12/02
Update Date (DUPD): 1995/08/04



Atom/Bond Notes:

1. CIP Descriptor: R
2. CIP Descriptor: S
3. CIP Descriptor: E

L6 ANSWER 1 OF 3 BEILSTEIN COPYRIGHT 2002 BEILSTEIN CDS MDL (Continued)

-72 | [alpha] | 1 g/100ml | CHCl3, methanol | 589 | 20 | 1

Reference(s):

1. Ramirez, Fausto; Marecek, James F.; Yemul, Shrishailam S., J.Org.Chem., CODEN: JOCEAH, 48(9), <1983>, 1417-1420; BABS-5578835

Nuclear Magnetic Resonance:

NMR

Description (.KW): Chemical shifts
Nucleus (.NUC): ³¹P
Solvents (.SOL): CDCl₃, methanol

Reference(s):

1. Ramirez, Fausto; Marecek, James F.; Yemul, Shrishailam S., J.Org.Chem., CODEN: JOCEAH, 48(9), <1983>, 1417-1420; BABS-5578835

Infrared Spectrum:

Descript | Ref.

ion |

(.KW) |

Bands | 1, 2

Reference(s):

1. Cremllyn, R.J.W.; Olsson, N.A., J.Chem.Soc.C, CODEN: JSOQAX, <1969>, 2305-2310
2. Cremllyn, R.J.W.; Olsson, N.A., J.Chem.Soc.C, CODEN: JSOQAX, <1971>, 2023-2027

UV and Visible Spectrum:

Description	Absorption	Ext./Abs. Coeff.	Ref.
-------------	------------	------------------	------

(.KW)	Maxima		
	(.AM)	(.EAC)	
	(nm)	(1/MOL*CM)	

Absorption maxima | 277, 287, 298 | 8270, 8690, 5090 | 1

Reference(s):

1. Ramirez, Fausto; Marecek, James F.; Yemul, Shrishailam S., J.Org.Chem., CODEN: JOCEAH, 48(9), <1983>, 1417-1420; BABS-5578835

Reaction:

RX

Reaction ID (.RID): 4142264
Reactant BRN (.RBRN): 7124081
Reactant (.RCT): 10,13-dimethyl-17-(1,4,5-trimethyl-hex-2-enyl)-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[*a*]phenanthren-3-ol
Product BRN (.PBRN): 4587778
Product (.PRO): Ergosteryldihydrogenphosphat
No. of React. Details (.NVAR): 1

Reaction Details:

RX

L6 ANSWER 1 OF 3 BEILSTEIN COPYRIGHT 2002 BEILSTEIN CDS MDL

(Continued)

Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	1
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	2
ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	3
NMR	Nuclear Magnetic Resonance	1
ORP	Optical Rotatory Power	1
UVS	UV and Visible Spectrum	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	3
RXPRO	Substance is Reaction Product	3

Melting Point:

Value	Solvent	Ref.
(MP)	(.SOL)	
(Cel)		
168		1
165 - 168	acetone	2
160	dioxane	3

Reference(s):

1. Cremllyn, R.J.W.; Olsson, N.A., J.Chem.Soc.C, CODEN: JSOQAX, <1971>, 2023-2027
2. Venner, H., J.Prakt.Chem., CODEN: JPCEAO, 12, <1960>, 59-73
3. Cremllyn, R.J.W.; Olsson, N.A., J.Chem.Soc.C, CODEN: JSOQAX, <1969>, 2305-2310

Optical Rotatory Power:

Value	Type	Concentr.	Solvent	Wavelen.	Temp.	Ref.
(ORP)	(.TYP)	(.C)	(.SOL)	(.W)	(.T)	
(deg)				(nm)	(Cel)	

L6 ANSWER 1 OF 3 BEILSTEIN COPYRIGHT 2002 BEILSTEIN CDS MDL (Continued)

Reaction RID (.RID): 4142264.1
Reaction Classification (.CL): Preparation
Reagent (.RGT): POCl₃, Py
Reference(s):
1. Venner, H., J.Prakt.Chem., CODEN: JPCEAO, 12, <1960>, 59-73

Reaction:

RX

Reaction ID (.RID): 4052975
Reactant BRN (.RBRN): 4738065
Reactant (.RCT): phosphordichloridic acid
ergosta-5,7,22t-trien-3.beta.-yl ester
Product BRN (.PBRN): 4587778
Product (.PRO): Ergosteryldihydrogenphosphat
No. of React. Details (.NVAR): 2

Reaction Details:

RX

Reaction RID (.RID): 4052975.1
Reaction Classification (.CL): Preparation
Reagent (.RGT): H₂O
Solvent (.SOL): dioxane
Reference(s):
1. Cremllyn, R.J.W.; Olsson, N.A., J.Chem.Soc.C, CODEN: JSOQAX, <1971>, 2023-2027

RX

Reaction RID (.RID): 4052975.2
Reaction Classification (.CL): Preparation
Reagent (.RGT): H₂O
Reference(s):
1. Cremllyn, R.J.W.; Olsson, N.A., J.Chem.Soc.C, CODEN: JSOQAX, <1969>, 2305-2310

Reaction:

RX

Reaction ID (.RID): 2128135
Reactant BRN (.RBRN): 2338604
Reactant (.RCT): ergosta-5,7,22t-trien-3.beta.-ol
Product BRN (.PBRN): 4587778
Product (.PRO): Ergosteryldihydrogenphosphat
No. of React. Details (.NVAR): 1


Reaction Details:

RX

Reaction RID (.RID): 2128135.1
Reaction Classification (.CL): Preparation
Yield (.YDT): 65 percent (BRN=4587778)
Reagent (.RGT): (1-phenyl-1,2-dibromoethyl)phosphonic acid, diisopropylethylamine
Solvent (.SOL): CH₂Cl₂
Time (.TIM): 15 hour (s)
Temperature (.T): 20 Cel
Reference(s):
1. Ramirez, Fausto; Marecek, James F.; Yemul, Shrishailam S., J.Org.Chem., CODEN: JOCEAH, 48(9), <1983>, 1417-1420; BABS-5578835

L6 ANSWER 2 OF 3 BEILSTEIN COPYRIGHT 2002 BEILSTEIN CDS MDL

Beilstein Records (BRN): 4585719
Beilstein Pref. RN (BPR): 85135-03-1
CAS Reg. No. (RN): 85135-03-1
Chemical Name (CN): phosphoric acid mono-(17-(4-ethyl-1,5-dimethyl-hex-2-enyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta<a>phenanthren-3-yl) ester
Autonom Name (AUN): phosphoric acid mono-(17-(4-ethyl-1,5-dimethyl-hex-2-enyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta<a>phenanthren-3-yl) ester
Molec. Formula (MF): C29 H49 O4 P
Molecular Weight (MW): 492.68
Lawson Number (LN): 5498
File Segment (FS): Stereo compound
Compound Type (CTYPE): isocyclic
Constitution ID (CONSID): 4130247
Tautomer ID (TAUTID): 4395171
Beilstein Citation (BSO): 6-06
Entry Date (DED): 1991/12/02
Update Date (DUPD): 1991/12/02



Atom/Bond Notes:
1. CIP Descriptor: R
2. CIP Descriptor: S
3. CIP Descriptor: Z

Field Availability:

L6 ANSWER 2 OF 3 BEILSTEIN COPYRIGHT 2002 BEILSTEIN CDS MDL (Continued)

1. Ramirez, Fausto; Marecek, James F.; Yemul, Shrishailam S., J.Org.Chem., CODEN: JOCEAH, 48(9), <1983>, 1417-1420; BABS-5578835

Nuclear Magnetic Resonance:

NMR

Description (.KW): Chemical shifts
Nucleus (.NUC): 31P
Solvents (.SOL): CDCl3, methanol

Reference(s):
1. Ramirez, Fausto; Marecek, James F.; Yemul, Shrishailam S., J.Org.Chem., CODEN: JOCEAH, 48(9), <1983>, 1417-1420; BABS-5578835

Reaction:

RX

Reaction ID (.ID): 2670244
Reactant BRN (.RBRN): 4707517
Reactant (.RCT): stigmaterol
Product BRN (.PBRN): 4585719
Product (.PRO): phosphoric acid mono-(17-(4-ethyl-1,5-dimethyl-hex-2-enyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta<a>phenanthren-3-yl) ester
No. of React. Details (.NVAR): 1

Reaction Details:

RX

Reaction RID (.RID): 2670244.1
Reaction Classification (.CL): Preparation
Yield (.YDT): 72 percent (BRN=4585719)
Reagent (.RGT): (1-phenyl-1,2-dibromoethyl)phosphonic acid, diisopropylethylamine
Solvent (.SOL): CH2Cl2
Time (.TIM): 15 hour(s)
Temperature (.T): 20 Cel
Reference(s):
1. Ramirez, Fausto; Marecek, James F.; Yemul, Shrishailam S., J.Org.Chem., CODEN: JOCEAH, 48(9), <1983>, 1417-1420; BABS-5578835

L6 ANSWER 2 OF 3 BEILSTEIN COPYRIGHT 2002 BEILSTEIN CDS MDL (Continued)

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	1
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
MP	Melting Point	1
NMR	Nuclear Magnetic Resonance	1
ORP	Optical Rotatory Power	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

Melting Point:

Value	Solvent	Ref.	Note
(MP)	(.SOL)		
(Cel)			

179 - 182 (dioxane) 1 1

Reference(s):

1. Ramirez, Fausto; Marecek, James F.; Yemul, Shrishailam S., J.Org.Chem., CODEN: JOCEAH, 48(9), <1983>, 1417-1420; BABS-5578835

Notes(s):

1. Decomposition. Crystallization with 1 Mol(s) H2O

Optical Rotatory Power:

Value	Type	Concentr.	Solvent	Wavelen.	Temp.	Ref.
(ORP)	(.TYP)	(.C)	(.SOL)	(.W)	(.T)	
(deg)				(nm)	(Cel)	

-38 [alpha] 1 g/100ml CHCl3, methanol 589 20 1

Reference(s):

L6 ANSWER 3 OF 3 BEILSTEIN COPYRIGHT 2002 BEILSTEIN CDS MDL

Beilstein Records (BRN): 3192627
Beilstein Pref. RN (BPR): 122295-88-9
CAS Reg. No. (RN): 122295-88-9
Chemical Name (CN): phosphoric acid diergosteryl ester
Autonom Name (AUN): phosphoric acid bis-(10,13-dimethyl-17-(1,4,5-trimethyl-hex-2-enyl)-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta<a>phenanthren-3-yl) ester
Molec. Formula (MF): C56 H87 O4 P
Molecular Weight (MW): 855.27
Lawson Number (LN): 5505
File Segment (FS): Stereo compound
Compound Type (CTYPE): isocyclic
Constitution ID (CONSID): 2360173
Tautomer ID (TAUTID): 3075093
Beilstein Citation (BSO): 3-06-00-03118
Entry Date (DED): 1990/02/15
Update Date (DUPD): 1991/09/20

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Atom/Bond Notes:

1. CIP Descriptor: R
2. CIP Descriptor: S
3. CIP Descriptor: E

Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	1
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
MP	Melting Point	1
ORP	Optical Rotatory Power	1
UVS	UV and Visible Spectrum	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	2
RXPRO	Substance is Reaction Product	2

L6 ANSWER 3 OF 3 BEILSTEIN COPYRIGHT 2002 BEILSTEIN CDS MDL (Continued)

Melting Point:

Value	Solvent	Ref.	Note
(MP)	(.SOL)		
(Cel)			

180 - 182	pyridine	1	1

Reference(s):

1. v. Euler; Wolf; Hellstroem, Chem.Ber., CODEN: CHBEAM, 62, <1929>, 2451, 2456

Notes(s):

1. Handbook

Optical Rotatory Power:

Value	Type	Concentr.	Solvent	Wavelen.	Temp.	Ref.	Note
(ORP)	(.TYP)	(.C)	(.SOL)	(.W)	(.T)		
(deg)				(nm)		(Cel)	

-68.9	[alpha]	c=2.7	CHCl3	589	20	1	1

Reference(s):

1. v. Euler; Rydbom, Sven.Kem.Tidskr., CODEN: SKTIAF, 41, <1929>, 223, 226

Notes(s):

1. Handbook

UV and Visible Spectrum:

Description	Solvent	Ref.	Note
(.KW)	(.SOL)		

Spectrum	ethanol	1	1

Reference(s):

1. v. Euler; Wolf; Hellstroem, Chem.Ber., CODEN: CHBEAM, 62, <1929>, 2451, 2456

Notes(s):

1. Handbook

Reaction:

RX	Reaction ID (.ID):	7912633
	Reactant BRN (.RBRN):	956581, 635680, 103233, 2338604
	Reactant (.RCT):	phosphorus oxychloride, propan-2-one, pyridine, ergosta-5,7,22t-trien-3.beta.-ol

L6 ANSWER 3 OF 3 BEILSTEIN COPYRIGHT 2002 BEILSTEIN CDS MDL (Continued)

Product BRN (.PBRN): 3192627
Product (.PRO): phosphoric acid diergosteryl ester
No. of React. Details (.NVAR): 1

Reaction Details:

RX

Reaction RID (.RID): 7912633.1
Reaction Classification (.CL): Chemical behaviour
Other Conditions (.COND): anschl. mit Wasser
Note(s) (.COM): Handbook
Reference(s):
1. v. Euler; Wolf; Hellstroem, Chem.Ber., CODEN: CHBEAM, 62, <1929>, 2451, 2456
2. v. Euler; Rydbom, Sven.Kem.Tidskr., CODEN: SKTIAF, 41, <1929>, 223, 226

Reaction:

RX

Reaction ID (.ID): 350192
Reactant BRN (.RBRN): 2338604
Reactant (.RCT): ergosta-5,7,22t-trien-3.beta.-ol
Product BRN (.PBRN): 3192627
Product (.PRO): phosphoric acid diergosteryl ester
No. of React. Details (.NVAR): 1

Reaction Details:

RX

Reaction RID (.RID): 350192.1
Reaction Classification (.CL): Preparation
Reagent (.RGT): acetone, pyridine, POCl3
Other Conditions (.COND): Eintragen des Reaktionsgemisches in Wasser
Note(s) (.COM): Handbook
Reference(s):
1. v. Euler; Wolf; Hellstroem, Chem.Ber., CODEN: CHBEAM, 62, <1929>, 2451, 2456

09/857,078

Page 14

=> d all 1-2

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS

AN 1961:81870 CAPLUS

DN 55:81870

OREF 55:15540g-1,15541a

TI Phosphoric esters of some DELTA.5-sterols

AU Venner, Harry

CS Deut. Akad. Wiss., Jena, Germany

SO J. prakt. Chem. (1960), 12, 59-73

DT Journal

LA Unavailable

CC 10J (Organic Chemistry: Steroids)

AB POC13 (I), pyridine (II), and several sterols under a variety of conditions yielded phosphoric acid monoester chlorides, free esters, and their cryst. II adducts if excess I was maintained. Disterylphosphates, II adducts, and disteryl ethers formed with excess sterol. Thus, 10 g. cholesterol (III) in 50 ml. II, added below 40.degree. to 8.8 ml. I in 50 ml. Me2CO, pptd. 12.7 g. III dichlorophosphate, m. 122.degree.. Refluxing with H2O gave 2 g. III phosphate, m. 195-6.degree. (EtOH), [.alpha.]24D -40.8.degree. (c 0.5, CHCl3). Addn. of 20 ml. I to 50 g. III in 200 ml. II below 40.degree. and pptn. with H2O after 1 hr. gave 15 g. di-III phosphate-II adduct, m. 195-6.degree. (EtOH). Crystn. from AcOH gave 11.2 g. di-III phosphate, m. 210.degree., [.alpha.]24D -22.15.degree. (c 0.5, CHCl3). EtOH mother liquors gave 10.2 g. dicholesteryl ether, m. 74.degree.. Similarly, ergosterol (IV) gave 2.6% IV phosphate, m. 165-8.degree., and 11.8% di-IV ether, m. 102.degree., [.alpha.]24D 88.1.degree. (c 1.0, CHCl3). Dilumisteryl phosphate (86%), m. 100-2.degree., was prepd. from 13.5 g. lumisterol and 1.9 ml. I with exclusion of O. Dicalciferyl phosphate, m. 143-4.5.degree., was prepd. from 10.6 g. calciferol2 and 2 ml. I. Dibenzyl phosphorochloridate and III in II at -40.degree. gave 26.8% III dibenzyl phosphate, m. 210.degree. (EtOAc). Hydrogenation with Pd on C in EtOH at room temp. and 1 atm. removed the benzyl groups only. Ergosteryl dibenzyl phosphate (7.8%) was prepd. from 20 g. dibenzyl phosphite and 13.2 g. ergosterol in 150 ml. II 3 hrs. at 60.degree., m. 180.degree.. Dibenzyl phosphoryl chloride and III in II at room temp. gave 59.5% 3.beta.-chloro-5-cholestene, m. 90-92.degree.. III phosphate adds 1 mole II from the gas phase at 22.degree.. K, Na, and Ca salts of the phosphates had indistinct m.ps. above 280.degree., except Ca III phosphate, m. 230-40.degree..

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS

AN 1961:81869 CAPLUS

DN 55:81869

OREF 55:15540c-g

TI Beckmann rearrangement of hecogenin acetate oxime

AU Bladon, P.; McMeekin, W.

CS Roy. Coll. Sci. Technol., Glasgow, UK

SO Chem. & Ind. (London) (1960) 1307

DT Journal

LA Unavailable

CC 10J (Organic Chemistry: Steroids)

GI For diagram(s), see printed CA issue.

AB Hecololactam acetate (I) with NaNO2 in HOAc and Ac2O at 0.degree. gave 8-10% hecololactone acetate (II), m. 298-301.degree., [.alpha.]D -65.0.degree. (all in CHCl3); the infrared spectrum was identical with that of an authentic specimen of II and was quite different from that of the isomeric isohecololactone acetate, m. 292-4.degree., [.alpha.]D -81.1.degree.. The material in the mother liquors heated with MeOH-KOH, then acidified, gave 90% anhydrohecolic acid (III), m. 220-3.degree., [.alpha.]D -39.degree., .lambda. 208 m.mu., .epsilon. 4400, which reduced with LiAlH4 gave anhydrohecolyl alc., m. 176-8.degree., [.alpha.]D -43.degree., as the sole product. Conversion of I into II and III, in both of which compds. the [11,12-bond still was intact, and in 100% total yields, proved that I had the structure shown. Cf. Mazur, CA 53, 18094d.

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:631950 CAPLUS

DOCUMENT NUMBER: 125:256745

TITLE: **Cosmetic** composition based on lipid vesicles containing acids and its use in topical application

INVENTOR(S): Terren, Nadia; Perrin, Martine; Michelet, Jacques

PATENT ASSIGNEE(S): Oreal S. A., Fr.

SOURCE: Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 728459	A1	19960828	EP 1996-400163	19960123
EP 728459	B1	19970326		
R: DE, ES, FR, GB, IT				
FR 2730928	A1	19960830	FR 1995-2136	19950223
FR 2730928	B1	19970404		
ES 2102919	T3	19970801	ES 1996-400163	19960123
CN 1136430	A	19961127	CN 1996-106076	19960222
JP 08245338	A2	19960924	JP 1996-36860	19960223
BR 9600613	A	19971230	BR 1996-613	19960223
US 5804216	A	19980908	US 1996-605921	19960223
			FR 1995-2136 A	19950223

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 125:256745

AB **Cosmetic** compns. based on lipid vesicles contg. acids, pH .ltoreq. 5, are disclosed. A **cosmetic** foundation contained Generol 122E5 1.6, hydrogenated lecithin 2.4, Me p-hydroxybenzoate 0.2, guanosine 0.01, glycerin 3, propylene glycol 3, palm oil 6.5, apricot kernel oil 9.5, Bu p-hydroxybenzoate 0.09, Pr p-hydroxybenzoate 0.1, volatile silicone 7158, vitamin E acetate 0.5, Givaudan 1, yellow iron oxide 0.89, brown iron oxide 0.49, black iron oxide 0.11, titanium oxide 5.51, preservative 0.3, Sepigel 305 2, mixt. of .alpha.-hydroxyacids 1, crosslinked starch 3, and water q.s. 100 g.


IT **4358-16-1D**, Cholesterol phosphate, alk. saltsRL: BUU (Biological use, unclassified); BIOL (Biological study); **USES****(Uses)**

(cosmetic compn. based on lipid vesicles contg. acids and its use in topical application)

RN 4358-16-1 CAPLUS

CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (ascorbyl-phosphoryl-cholesterol for cosmetic uses)
 RN 313055-94-6 CAPLUS
 CN 1-Ascorbic acid, 2(or 3)-[(3.beta.)-cholest-5-en-3-yl hydrogen phosphate], sodium salt (9CI) (CA INDEX NAME)

CM 1

CRN 4358-16-1
 CMF C27 H47 O4 P


Absolute stereochemistry.



CM 2

CRN 50-81-7
 CMF C6 H8 O6

Absolute stereochemistry.



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:573506 CAPLUS
 DOCUMENT NUMBER: 133:169183
 TITLE: Cosmetic and/or dermatological composition in the form of an oil-in-water emulsion formed by lipid vesicles dispersed in an aqueous phase containing at least one active hydrophilic acid
 INVENTOR(S): Ravau, Danielle; Laugier, Jean-Pierre
 PATENT ASSIGNEE(S): L'Oreal, Fr.
 SOURCE: Eur. Pat. Appl., 15 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1027878	A1	20000816	EP 1999-403289	19991227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2789329	A1	20000811	FR 1999-1387	19990205
FR 2789329	B1	20010302		
KR 2000057824	A	20000925	KR 2000-4263	20000128
BR 2000000613	A	20010502	BR 2000-613	20000202
JP 2000229840	A2	20000822	JP 2000-26700	20000203
US 6416768	B1	20020709	US 2000-499391	20000207
			FR 1999-1387	A 19990205

PRIORITY APPLN. INFO.: MARPAT 133:168183
 OTHER SOURCE(S):
 AB The title compns. are disclosed. A double-compartment bottle contained polyglyceryl-2-stearate 0.2, PEG-8 stearate 0.135, Amisoft HS-20 0.09, isocetyl stearate 0.7, squalane 1.3, and water 7.075 g. The emulsion had a viscosity of about 7 cP at 2.degree. and pH = 7.3. The top of the bottle contained 0.5 g of ascorbic acid. By addn. of the ascorbic acid to the emulsion the pH decreased to 3.3 and the viscosity increased to 850 cP at 25.degree. forming a white cream.

IT 4358-16-1D, Cholesterol phosphate, alkali salts
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (uses)
 (cosmetic and/or dermatol. compn. in form of oil-in-water emulsion formed by lipid vesicles dispersed in aq. phase contg. at least one active hydrophilic acid)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:553219 CAPLUS
 DOCUMENT NUMBER: 133:155164
 TITLE: Nanoemulsion from alkoxyated alkenyl succinates or alkoxyated alkenyl succinates of glucose and its cosmetic, dermatologic, ophthalmologic, and/or pharmaceutical uses
 INVENTOR(S): Simonnet, Jean-thierry; Sonnevill, Odile; Legret, Sylvie
 PATENT ASSIGNEE(S): L'Oreal, Fr.
 SOURCE: Eur. Pat. Appl., 11 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1025898	A1	20000809	EP 2000-400009	20000104
EP 1025898	B1	20020123		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2788980	A1	20000804	FR 1999-1178	19990202
FR 2788980	B1	20020412		
AT 212248	E	20020215	AT 2000-400009	20000104
ES 2173848	T3	20021101	ES 2000-400009	20000104
US 6461625	B1	20021008	US 2000-489839	20000124
BR 2000000417	A	20000912	BR 2000-417	20000127
JP 2000226314	A2	20000815	JP 2000-24373	20000201
CN 1270019	A	20001018	CN 2000-101988	20000201
			FR 1999-1178	A 19990202

PRIORITY APPLN. INFO.: MARPAT 133:155164
 OTHER SOURCE(S):
 AB Cosmetic, dermatol., ophthalmol., and/or pharmaceutical nanoemulsions with oil globules <100 nm contain surfactants chosen from alkoxyated alkenyl succinates or alkoxyated alkenyl succinates of glucose and an oil having mol. wt. >400, the ratio of oily phase to surfactant is 2:10. The nanoemulsion is transparent and stable over storage. A make-up remover fluid contained Acylglutamate HS21 0.5 isocetyl stearate 10, iso-Pr myristate 5, ethoxylated dihexadecenyl succinate 4.5, 1 M sodium hydroxide 3, glycerin 5, dipropylene glycol 10, and water 62%.

IT 4358-16-1D, Cholesteryl phosphate, alkali metal salts
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (uses)
 (nanoemulsion from alkoxyated alkenyl succinates or alkoxyated alkenyl succinates of glucose and its cosmetic, dermatol., ophthalmol. and/or pharmaceutical uses)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:493088 CAPLUS
 DOCUMENT NUMBER: 133:124937
 TITLE: Cosmetic, dermatology, pharmaceutical and/or ophthalmology composition containing nanoemulsion based on alkylether citrates
 INVENTOR(S): Simonnet, Jean-Tierry; Legret, Sylvie; Sonnevill, Odile
 PATENT ASSIGNEE(S): L'oreal, Fr.
 SOURCE: Eur. Pat. Appl., 9 pp.
 CODEN: EPAXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1020219	A1	20000719	EP 1999-402914	19991123
EP 1020219	B1	20010321		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2788449	A1	20000721	FR 1999-408	19990114
FR 2788449	B1	20010216		
AT 199841	E	20010415	AT 1999-402914	19991123
ES 2157686	T3	20010816	ES 1999-402914	19991123
KR 2000052504	A	20000825	KR 1999-58632	19991217
US 6413527	B1	20020702	US 2000-478408	20000106
JP 2000212030	A2	20000802	JP 2000-4013	20000112
PRIORITY APPL. INFO.: FR 1999-408 A 19990114				

OTHER SOURCE(S): MARPAT 133:124937
 AB Nanoemulsions comprising anionic surfactants of the type alkylether citrates, where the av. size of globules is <100 nm, and the ratio of oil phase to surfactant is 2:10 are used in cosmetic, dermatol., pharmaceutical and/or ophthalmol. compns. The emulsions are transparent and stable and are used for moisturizing skin, mucosa and hair, and as collyre for the treatment eyes. A make-up remover fluid contained Acrylgumate HS21 0.5, isocetyl stearate 10, iso-Pc myristate 5% in the oil phase, and Wiconol 3129 4.5, NaOH 0.5, glycerin 5, dipropylene glycol 10, and water 64.5% in the aq. phase. The av. size of the globules in the transparent nanoemulsion was 54 nm.
 IT 4358-16-1D, Cholesteryl phosphate, alkali metal salts
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (cosmetic, dermatol., pharmaceutical and/or ophthalmol. compn. contg. nanoemulsion based on alkylether citrates)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L5 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:475431 CAPLUS
 DOCUMENT NUMBER: 133:75967
 TITLE: Block ethylene oxide-propylene oxide copolymer surfactant for oil-in-water nanoemulsions, especially for cosmetics and ophthalmic preparations
 INVENTOR(S): Simonnet, Jean Thierry; Sonnevill, Odile; Legret, Sylvie
 PATENT ASSIGNEE(S): L'oreal, Fr.
 SOURCE: Eur. Pat. Appl., 11 pp.
 CODEN: EPAXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1018363	A1	20000712	EP 1999-402913	19991123
EP 1018363	B1	20010321		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2788007	A1	20000707	FR 1999-31	19990105
FR 2788007	B1	20010209		
AT 199840	E	20010415	AT 1999-402913	19991123
ES 2157685	T3	20010816	ES 1999-402913	19991123
KR 2000052462	A	20000825	KR 1999-57227	19991213
JP 2000198711	A2	20000718	JP 1999-361819	19991220
US 2002015721	A1	20020207	US 2000-477715	20000105
US 6464990	B2	20021015		
PRIORITY APPL. INFO.: FR 1999-31 A 19990105				

OTHER SOURCE(S): MARPAT 133:75967
 AB Nanoemulsions, contg. 2-40 wt.% oil phase, with HLB 2-16, av. oil droplet size <100 nm (preferably 20-75 nm), and a 2-10:1 oil phase-surfactant wt. ratio, contain an ethylene oxide-propylene oxide block copolymer surfactant, of general formula HO(C2H4O)_x(C3H6O)_y(C2H4O)_zH, in which x, y, and z are whole nos. such that x + y + z = 2-100, and y = 14-60. The nanoemulsions also contain at least one amphiphilic ionic lipid selected from anionic amphiphiles, cationic amphiphiles, and alkylsulfonates. The ionic amphiphilic lipids are selected from: (1) alkali salts of dicetyl and dimyristyl phosphate, (2) alkali salts of cholesterol sulfate, (3) alkali salts of cholesterol phosphate, (4) salts of lipo amino acids, (5) sodium salts of phosphatidic acids, (6) phospholipids, (7) alkylsulfonates of formula R-CH(SO3M)-C(=O)-O-CH2CH2-COCH3 (in which R = C16-22-alkyl and M is an alkali metal), and (8) quaternary ammonium salts, fatty amines, and fatty amine salts. The compns. have application as nanoemulsions for cosmetics, dermatol., and eye care.
 IT 4358-16-1D, Cholesterol phosphate, alkali metal salts
 RL: TEM (Technical or engineered material use); USES (Uses)
 (nanoemulsions contg. block ethylene oxide-propylene oxide copolymer surfactant for oil-in-water nanoemulsions, esp. for cosmetics and ophthalmic preps.)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L5 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:456698 CAPLUS
 DOCUMENT NUMBER: 133:63637
 TITLE: Nanoemulsion based on ethoxylated fatty ethers or esters and uses thereof in the fields of cosmetics, dermatology and/or ophthalmology
 INVENTOR(S): Simonnet, Jean-Thierry; Sonnevill, Odile; Legret, Sylvie
 PATENT ASSIGNEE(S): L'Oreal, Fr.
 SOURCE: Eur. Pat. Appl., 11 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1016453	A1	20000705	EP 1999-402855	19991117
EP 1016453	B1	20010905		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2787703	A1	20000630	FR 1998-16570	19981229
FR 2787703	B1	20010126		
AT 205111	E	20010915	AT 1999-402855	19991117
ES 2163926	T3	20020201	ES 1999-402855	19991117
BR 9906206	A	20010206	BR 1999-6206	19991210
KR 2000052471	A	20000825	KR 1999-57463	19991214
JP 2000191503	A2	20000711	JP 1999-371720	19991227
CN 1266679	A	20000920	CN 1999-127471	19991228
US 6375960	B1	20020423	US 1999-474074	19991229

PRIORITY APPLN. INFO.: FR 1998-16570 A 19981229
 OTHER SOURCE(S): MARPAT 133:63637
 AB A nanoemulsion having oil globules with av. size <100 nm contains (1) a surfactant, which is solid at .ltoreq.45.degree.C, chosen from ethoxylated fatty ethers or esters, and (2) an oil having mol. wt. >400, where the wt. ratio of oil phase to surfactant is 2-10:1. The surfactant can be an ethoxylated ether of behenic alc. (5-30 ethoxy units) or stearyl alc. (2 ethoxy units), an ethoxylated ester of stearic acid (40 ethoxy units) or behenic acid (8 ethoxy units), or their mixts. The nanoemulsion is transparent and stable with turbidity 60-600 NTU. It can be used in cosmetics and topical pharmaceuticals or ophthalmol. formulations. The nanoemulsion can be used for moisturizing dry skin and mucous membranes, treatment of hair, and as collyrium (eye lotion) for treatment of the eyes. In an example, a make-up removing liq. contained Brij 72 4.5, disodium N-stearoyl L-glutamic acid (Acylglutamate HS21) 0.5, isocetyl stearate 10, iso-Pr myristate 5, glycerin 5, dipropylene glycol 10 and water 65%. The transparent gel had globule size of 47 nm and turbidity of 222 NTU.
 IT 4358-16-1D, Cholesterol phosphate, alkali metal salts
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nanoemulsion based on ethoxylated fatty ethers or esters and uses thereof in fields of cosmetics, dermatol. and/or ophthalmol.)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

L5 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)
 Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:441331 CAPLUS
 DOCUMENT NUMBER: 133:63629
 TITLE: Nanoemulsion based on fatty esters of phosphoric acid and uses thereof in the fields of cosmetics, dermatology, pharmaceuticals and/or ophthalmology
 INVENTOR(S): Simonnet, Jean-Thierry; Legret, Sylvie; Sonnevill, Odile
 PATENT ASSIGNEE(S): L'Oreal, Fr.
 SOURCE: Eur. Pat. Appl., 9 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1013338	A1	20000628	EP 1999-402856	19991117
EP 1013338	B1	20011010		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2787728	A1	20000630	FR 1998-16370	19981223
FR 2787728	B1	20010126		
AT 206632	E	20011015	AT 1999-402856	19991117
ES 2165725	T3	20020316	ES 1999-402856	19991117
JP 2000191502	A2	20000711	JP 1999-361818	19991220
US 6274150	B1	20010814	US 1999-468325	19991221

PRIORITY APPLN. INFO.: FR 1998-16370 A 19981223
 OTHER SOURCE(S): MARPAT 133:63629
 AB A nanoemulsion having oil globules with av. size <100 nm contains an anionic surfactant chosen from fatty esters of phosphoric acid and its ethoxylated derivs., and an oil having mol. wt. >400; the ratio of the oil phase to surfactant is 2:10. The nanoemulsion is transparent and stable. The nanoemulsion is used for moisturizing dry skin and mucous, treatment of hair, and as collyrium for the treatment of eye. A make-up remover contained disodium N-stearoyl L-glutamic acid (Acylglutamate HS21) 0.5, isocetyl stearate 10, iso-Pr palmitate 5, glycerin 5, dipropylene glycol 10, 1N sodium hydroxide 5, Hostaphat CG120 4.5, and water 60%. The transparent gel had globule size of 57 nm and turbidity of 250 NTU.
 IT 4358-16-1D, Cholesterol phosphate, alkali salts
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (nanoemulsion based on fatty esters of phosphoric acid and uses thereof in the fields of cosmetics, dermatol., pharmaceuticals and/or ophthalmol.)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L5 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:420746 CAPLUS
 DOCUMENT NUMBER: 133:48692
 TITLE: Nanoemulsion based on fatty esters of glycerol and uses thereof in the fields of cosmetics, dermatology and/or ophthalmology
 INVENTOR(S): Simonnet, Jean Thierry; Sonnevill, Odile; Legret, Sylvie
 PATENT ASSIGNEE(S): L'Oreal, Fr.
 SOURCE: Eur. Pat. Appl., 11 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1010416	A1	20000621	EP 1999-402915	19991123
EP 1010416	B1	20011004		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2787326	A1	20000623	FR 1998-15950	19981217
FR 2787326	B1	20010126		
AT 206300	E	20011015	AT 1999-402915	19991123
ES 2167993	T3	20020516	ES 1999-402915	19991123
BR 9907333	A	20010206	BR 1999-7333	19991208
JP 2000178132	A2	20000627	JP 1999-353752	19991213
KR 2000048108	A	20000725	KR 1999-57231	19991213
CN 1265923	A	20000913	CN 1999-126428	19991216
US 6541018	B1	20030401	US 1999-461753	19991216

PRIORITY APPLN. INFO.: FR 1998-15950 A 19981217
 OTHER SOURCE(S): MARPAT 133:48692
 AB A nanoemulsion having oil globules with av. size <100 nm contains a surfactant, which is solid at .ltoreq.45.degree., chosen from fatty acid esters of glycerol and an oil having mol. wt. >400; the ratio of the oil phase to surfactant is 2:10. The nanoemulsion is transparent and stable. The nanoemulsion is used for moisturizing dry skin and mucous, treatment of hair, and as collyrium for the treatment of eye. A make-up liq. contained Nikkol Decaglyn 35 4.5, disodium N-stearoyl L-glutamic acid (Acylglutamate HS21) 0.5, isocetyl stearate 10, iso-Pr myristate 5, glycerin 5, dipropylene glycol 10, and water 65%. The transparent gel had globule size of 50 nm and turbidity of 176 NTU.
 IT 4358-16-1D, Cholesterol phosphate, alkali salts
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (uses)
 (nanoemulsion based on fatty esters of glycerol and uses thereof in fields of cosmetics, dermatol. and/or ophthalmol.)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L5 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:420745 CAPLUS
 DOCUMENT NUMBER: 133:48691
 TITLE: Nanoemulsion based on fatty esters of oxyethylated or non-oxyethylated sorbitan and uses thereof in the fields of cosmetics, dermatology and/or ophthalmology
 INVENTOR(S): Simonnet, Jean-Thierry; Sonnevill, Odile; Legret, Sylvie
 PATENT ASSIGNEE(S): L'Oreal, Fr.
 SOURCE: Eur. Pat. Appl., 10 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1010415	A1	20000621	EP 1999-402875	19991119
EP 1010415	B1	20020102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2787325	A1	20000623	FR 1998-15949	19981217
FR 2787325	B1	20010126		
AT 211380	E	20020115	AT 1999-402875	19991119
ES 2171068	T3	20020816	ES 1999-402875	19991119
BR 9907331	A	20010206	BR 1999-7331	19991207
JP 2000178131	A2	20000627	JP 1999-353750	19991213
KR 2000048105	A	20000725	KR 1999-57228	19991213
US 6335022	B1	20020101	US 1999-459580	19991213
CN 1265879	A	20000913	CN 1999-126429	19991216

PRIORITY APPLN. INFO.: FR 1998-15949 A 19981217
 OTHER SOURCE(S): MARPAT 133:48691
 AB A nanoemulsion having oil globules with av. size <100 nm contains (1) a surfactant, which is solid at .ltoreq.45.degree., chosen from fatty esters of sorbitan or ethoxylated sorbitan, (2) an oil having mol. wt. >400, (3) and an amphiphilic ionic lipid chosen from alkali salts of dicetyl or dimyristyl phosphate, alkali salts of cholesterol sulfate, and cholesterol phosphate, liposaminoadids, sodium phosphates, amphiphilic cationic lipids and derivs. of alkyl sulfonic acids; the ratio of the oil phase to surfactant is 2:10. The surfactant used is chosen from sorbitan monostearate, sorbitan monopalmitate, and ethoxylated sorbitan triacetate. The nanoemulsion is transparent and stable. The nanoemulsion is used for moisturizing dry skin and mucous, treatment of hair, and as collyrium for the treatment of eye. A make-up fluid contained Tween-65 4.5, disodium N-stearoyl L-glutamic acid (Acylglutamate HS21) 0.5, isocetyl stearate 10, iso-Pr palmitate 5, glycerin 5, dipropylene glycol 10, and water 65%. The transparent gel had globule size of 44 nm and turbidity of 168 NTU.
 IT 4358-16-1D, Cholesterol phosphate, alkali salts
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (uses)
 (nanoemulsion based on fatty esters of oxyethylated or non-oxyethylated sorbitan and uses thereof in fields of cosmetics, dermatol. and/or ophthalmol.)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L5 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2000:420744 CAPLUS
DOCUMENT NUMBER: 133:48690
TITLE: Nanoemulsion based on mixed esters of a fatty acid or alcohol, of a carboxylic acid and glycerol, and uses thereof in the cosmetic, dermatological and/or ophthalmological fields
INVENTOR(S): Sonnevile, Odile; Simonnet, Jean-Thierry; Legret, Sylvie
PATENT ASSIGNEE(S): L'Oreal, Fr.
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1010414	A1	20000621	EP 1999-402837	19991116
EP 1010414	B1	20010404		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2787026	A1	20000616	FR 1998-15764	19981214
FR 2787026	B1	20010112		
AT 200218	E	20010415	AT 1999-402837	19991116
ES 2158728	T3	20010901	ES 1999-402837	19991116
JP 2000178129	A2	20000627	JP 1999-352422	19991210
US 6419946	B1	20020716	US 1999-459581	19991213

PRIORITY APPL. INFO.: FR 1998-15764 A 19981214
OTHER SOURCE(S): MARPAT 133:48690
AB A nanoemulsion having oil globules with av. size <100 nm contains a surfactant, which is solid at .ltoreq.45.degree., chosen from esters of fatty acids or fatty alcs., carboxylic acid and glycerol, and an oil having mol. wt. >400; the ratio of the oil phase to surfactant is 2:10. The nanoemulsion is transparent and stable. The nanoemulsion is used for moisturizing dry skin and mucous, treatment of hair, and as collyrium for the treatment of eye. A make-up fluid contained Isisor 780K 4.5, disodium N-stearoyl L-glutamic acid (Acylglutamate HS21) 0.5, isocetyl stearate 20, iso-Pr palmitate 5, glycerin 5, dipropylene glycol 10, and water 65%. The transparent gel had globule size of 57 nm and turbidity of 251 NTU.
IT 4358-16-1D, Cholesterol phosphate, alkali salts
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(nanoemulsion based on mixed esters of fatty acid or alc., of carboxylic acid and glycerol, and uses thereof in cosmetic, dermatol. and/or ophthalmol. fields)
RN 4358-16-1 CAPLUS
CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:420743 CAPLUS
DOCUMENT NUMBER: 133:63593
TITLE: Nanoemulsion based on fatty acid esters or ethers of sugar and uses thereof in the cosmetic, dermatological and/or ophthalmological fields
INVENTOR(S): Simonnet, Jean-Thierry; Sonnevile, Odile; Legret, Sylvie
PATENT ASSIGNEE(S): L'Oreal, Fr.
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1010413	A1	20000621	EP 1999-402836	19991116
EP 1010413	B1	20021120		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2787027	A1	20000616	FR 1998-15765	19981214
FR 2787027	B1	20010112		
AT 227967	E	20021215	AT 1999-402836	19991116
BR 9907330	A	20010206	BR 1999-7330	19991206
JP 2000178130	A2	20000627	JP 1999-352423	19991210
CN 1257704	A	20000628	CN 1999-126145	19991213
KR 2000048107	A	20000725	KR 1999-57230	19991213

PRIORITY APPL. INFO.: FR 1998-15765 A 19981214
OTHER SOURCE(S): MARPAT 133:63593
AB A nanoemulsion having oil globules with av. size <100 nm contains a surfactant, which is solid at .ltoreq.45.degree., chosen from fatty acid esters or ethers of sugars and an oil having mol. wt. >400; the ratio of the oil phase to surfactant is 2:10. The nanoemulsion is transparent and stable. The nanoemulsion is used for moisturizing dry skin and mucous, treatment of hair, and as collyrium for the treatment of eye. A make-up gel contained Crodesta F50 4.5, disodium N-stearoyl L-glutamic acid (Acylglutamate HS21) 0.5, isocetyl stearate 20, C11-13 isoparaffin 2.5, isohexadecane 2.5, glycerin 5, dipropylene glycol 10, and water 55%. The transparent gel had globule size of 45 nm and turbidity of 260 NTU.
IT 4358-16-1D, Cholesterol phosphate, alkali salts
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(nanoemulsion based on fatty acid esters or ethers of sugar and uses thereof in cosmetic, dermatol. and/or ophthalmol. fields)
RN 4358-16-1 CAPLUS
CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:505729 CAPLUS
DOCUMENT NUMBER: 127:126356
TITLE: Stable dispersion of a water-immiscible phase in an aqueous phase using surface-active silicone vesicles
INVENTOR(S): Simonnet, Jean-Thierry
PATENT ASSIGNEE(S): L'Oreal S. A., Fr.
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 780113	A1	19970625	EP 1996-402526	19961122
EP 780113	B1	20020904		
R: DE, ES, FR, GB, IT				
FR 2742674	A1	19970627	FR 1995-15292	19951221
FR 2742674	B1	19980206		
ES 2182958	T3	20030316	ES 1996-402526	19961122
JP 09175930	A2	19970708	JP 1996-341881	19961220
JP 3137592	B2	20010226		
US 5958433	A	19990928	US 1996-771840	19961223

PRIORITY APPLN. INFO.: FR 1995-15292 A 19951221
OTHER SOURCE(S): MARPAT 127:126356
AB Stable dispersion of a water-immiscible phase in an aq. phase using surface-active silicone vesicles are claimed (Markush structure given). The dispersion is used in cosmetics for the treatment of skin, mucosa, nail, hair, and esp. greasy skin
A cream contained a silicone surfactant (Dow Corning 2-5695) 5, acylglutamate HS21 0.6, glycerin 3, volatile silicone 10, jojoba oil 10, Carbopol-980 0.42, preservative 0.3, triethanolamine q.s. pH = 6, and water q.s. 100%
IT 4358-16-1D, Cholesterolphosphate, alkali metal salts
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (uses)
(stable dispersion of water-immiscible phase in aq. phase using surface-active silicone vesicles)
RN 4358-16-1 CAPLUS
CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)

L5 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:479334 CAPLUS
DOCUMENT NUMBER: 127:113133
TITLE: Transparent nanoemulsion based on silicone surfactants, and its use in cosmetics
INVENTOR(S): Simonnet, Jean-Thierry
PATENT ASSIGNEE(S): L'Oreal S. A., Fr.
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 780114	A1	19970625	EP 1996-402548	19961126
EP 780114	B1	20021218		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
FR 2742676	A1	19970627	FR 1995-15291	19951221
FR 2742676	B1	19980206		
AT 229792	E	20030115	AT 1996-402548	19961126
BR 9604724	A	19980901	BR 1996-4724	19961219
JP 09175933	A2	19970708	JP 1996-341882	19961220
JP 3040355	B2	20000515		
CN 1156586	A	19970813	CN 1996-117923	19961220
US 6120778	A	20000919	US 1996-772724	19961223

PRIORITY APPLN. INFO.: FR 1995-15291 A 19951221
OTHER SOURCE(S): MARPAT 127:113133
AB Transparent oil/in/water cosmetic emulsions where the av. size of oil globules is <100 nm contain silicone surfactants. A cosmetic liq. for greasy skin contained silicone surfactant (DC 2-5698) 5, dodecamethylcyclotetrasiloxane 6, decamethylcyclotetrasiloxane 6, silicone gum Q2-1403 3, abs. ethanol 15, glycerin 5, and water q.s. 100%
IT 4358-16-1D, Cholesterol phosphate, alkali salts
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (uses)
(transparent oil/in/water cosmetic emulsions contg. silicone surfactants)
RN 4358-16-1 CAPLUS
CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

